Nuertingen

• Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended recruitment
  2022-500290-14-01 4 2023-05-11 Colitis ulcerative
• Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended recruitment
  2023-507187-39-00 5 2023-03-23 High-Risk Non-muscle-invasive Bladder Cancer
• Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit … Ended recruitment
  2024-511209-49-00 6 2022-04-26 Patients with hormone receptor positive HER2 negative locally advanced
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended recruitment
  2023-506365-64-00 5 2020-10-16 Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
• Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio … Ended recruitment
  2024-516481-11-00 5 2020-09-22 Metastatic Castration-Resistant Prostate Cancer
• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP … Ended recruitment
  2023-504998-20-00 5 2020-09-18 Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
• CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi … Ended recruitment
  2023-509089-39-00 5 2020-07-01 Non-Muscle Invasive Bladder Cancer
• TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT … Ended recruitment
  2023-509087-20-00 5 2019-04-16 Metastatic Castration-resistant Prostate Cancer
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Ended recruitment
  2023-505341-23-00 5 2018-07-27 Non-muscle invasive bladder cancer
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Ended
  2023-503919-15-00 3 2024-01-09 Prostatic Neoplasms
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma
• A Study Testing a New Drug (ALT-803) With BCG to Treat Early-Stage Bladder Cancer Ended
  2025-521223-78-00 4 Non-Muscle Invasive Bladder Cancer

Showing 25–44 of 44 trials